首頁 > 市場調查報告書 > 醫療設備

體外診斷

市場調查報告書

商品編碼

1316234

全球臨床診斷市場 - 2023-2030 年

Global Clinical Diagnostics Market - 2023-2030

出版日期: 2023年07月27日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

2022 年，全球臨床診斷市場規模達到732 億美元，預計到2030 年將達到1,100 億美元，實現利潤豐厚的成長。在預測期內（2023-2030 年），全球臨床診斷市場預計將呈現5.3% 的年複合成長率。

在分子診斷方法中，對遺傳物質（DNA 或RNA）進行分析，以發現與疾病相關的遺傳變異、突變或特定生物標記。被稱為聚合酶鏈反應（PCR）的常用分子技術可擴增和檢測特定的DNA 序列。基因檢測、傳染病檢測、癌症分析和遺傳病檢測都使用分子診斷技術。

市場動態

活躍的主要參與者推動了預測期內全球臨床診斷市場的成長

2023 年2 月，羅氏公司表示，為了進一步推動其研究和創新工作，該公司加強了與楊森生物技術公司的合作，共同開發用於標靶治療的輔助診斷產品。

隨著新合作關係的擴大，羅氏和楊森將有更多的選擇，共同開展精準醫療領域的輔助診斷項目，包括免疫組化（IHC）、數位病理學、新一代測序、聚合酶鏈反應和免疫測定。

技術進步為全球臨床診斷市場帶來成長機會

2023 年3 月，塔塔家族新成立的醫療保健公司塔塔醫療與診斷公司（Tata MD）與總部位於欽奈的安德森診斷與實驗室公司（Anderson Diagnostics & Labs，ADL）合作，努力實現本地開發的Tata MD CHECK 的標準化並降低新感染率。

通過與ADL 臨床專家的合作，"印度製造"的Tata MD CHECK 診斷試劑盒現在可以迅速推廣。 ADL已經成功完成了超過10,000次COVID測試，使用的是基於Feluda CRISPR平台、經DGCA批准的新型診斷解決方案。 "在對10,000 多份樣本進行測試和驗證後，我們相信這項技術既是最前沿的，也是世界上最好的。

COVID-19 影響分析

COVID-19 大流行對臨床診斷市場產生了重大影響。 COVID-19 大流行引發了臨床診斷研究與開發。專為檢測COVID-19 而開發的新診斷方法、技術和平台迅速發展起來。這些發展有助於抗擊大流行病，並產生了有助於整個臨床診斷行業的新想法和新資訊。

俄烏衝突分析

俄烏戰爭對臨床診斷市場的影響是複雜和多方面的。由於缺乏基礎設施、資源和知識，在受衝突影響的地區可能很難獲得新的診斷技術。尖端診斷技術（包括分子診斷或成像技術）的使用和獲取可能會受到限制，這可能會影響診斷服務的準確性和徹底性。

Market Overview

The global clinical diagnostics market reached US$ 73.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 110.0 billion by 2030. The global clinical diagnostics market is expected to exhibit a CAGR of 5.3% during the forecast period (2023-2030).

In molecular diagnostic methods, genetic material (DNA or RNA) is analyzed to find genetic variants, mutations, or particular biomarkers linked to diseases. The commonly used molecular technique known as polymerase chain reaction (PCR) amplifies and detects particular DNA sequences. Genetic testing, infectious disease testing, cancer profiling, and the detection of genetic diseases all use molecular diagnostics.

Market Dynamics

Active Major Players are Boosting the Global Clinical Diagnostics Market Growth During the Forecast Period

In February 2023, In order to further boost its research and innovation efforts, Roche stated that it had increased its partnership with Janssen Biotech Inc. to develop companion diagnostics for targeted treatments.

With the new, enlarged partnership, Roche and Janssen will have more options to work together on companion diagnostics projects in the area of precision medicine, including immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays.

Technological Advancements Provide Global Clinical Diagnostics Market Growth Opportunities

In March 2023, In an effort to standardize the locally developed Tata MD CHECK and reduce the rate of new infections, Tata Medical and Diagnostics (Tata MD), a new healthcare company from the Tata family, has partnered with Chennai-based Anderson Diagnostics & Labs (ADL).

The "Made-in-India" Tata MD CHECK diagnostic kit can now be scaled up quickly due to the collaboration with ADL's clinical experts. ADL has already successfully completed over 10,000 COVID tests using this new, DGCA-approved, novel diagnostic solution based on the Feluda CRISPR Platform. "After testing and validating more than 10,000 samples, we believe this technology to be both cutting edge and on par with the best in the world.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the clinical diagnostics market. Clinical diagnostics research and development have been sparked by the COVID-19 pandemic. New diagnostic assays, technologies, and platforms made specifically for the detection of COVID-19 have developed quickly. These developments have aided in the fight against the pandemic and have generated new ideas and information that will help the clinical diagnostics industry as a whole.

Russia-Ukraine Conflict Analysis

The impact of the Russia-Ukraine war on the clinical diagnostics market is complex and multifaceted. Due to a lack of infrastructure, resources, and knowledge, access to new diagnostic technology may be difficult in conflict-affected areas. The use and accessibility of cutting-edge diagnostic techniques, including molecular diagnostics or imaging technology, may be constrained, which could have an impact on the accuracy and thoroughness of diagnostic services.

Segment Analysis

The global clinical diagnostics market is segmented based on test, product, end-user, and region.

The Lipid Panel Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period

The lipid panel segment accounted for the highest market stake accounting for approximately 32.3% of the clinical diagnostics market in 2022. The lipid panel measures different lipids (fats) and the characteristics that go along with them in the bloodstream. It offers significant details on a person's lipid profile and cholesterol levels, which are essential markers of cardiovascular health.

Low-density lipoprotein (LDL) and high-density lipoprotein (HDL) cholesterol are both measured as well as the overall amount of cholesterol in the blood. Healthcare providers can determine a patient's risk for cardiovascular disease based on the findings of a lipid panel test and offer medication, lifestyle changes, or other therapies as necessary.

Geographical Analysis

Asia Pacific is Expected to hold Around 25.7% Share of this Market due to Increasing Collaborations and Partnerships Among the Key Players, and Advancement in Clinical Diagnostics

Asia Pacific is expected to hold around 25.7% share of this market. For instance, in May 2023, a high-end diagnostic solutions provider called Core Diagnostics, with its headquarters in Gurugram, announced the opening of a new satellite facility in East Delhi's Hargobind Enclave. With this strategic growth, the company hopes to increase its testing capabilities and give patients and healthcare professionals better access to high-quality diagnostic services.

The satellite lab is a crucial component of Core Diagnostics' strategic expansion plan, which aims to increase the company's testing capacity and satisfy the increasing demand for quality and timely diagnostic services. By bringing superior diagnostic options closer to healthcare professionals and patients, they are able to give them the precise information they need to make prompt medical decisions.

Competitive Landscape

The major global players in the market include: Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, Thermo Fisher Scientific among others.

Why Purchase the Report?

To visualize the global clinical diagnostics market segmentation based on the test, product, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of clinical diagnostics market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global clinical diagnostics market report would provide approximately 61 tables, 61 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Test
3.2. Snippet by Product
3.3. Snippet by End-user
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising burden of disease
- 4.1.2. Restraints
  - 4.1.2.1. Stringent regulatory requirements
- 4.1.3. Opportunity
  - 4.1.3.1. Technological advancements
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. Artificial Intelligence Analysis

9. By Test

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 9.1.2. Market Attractiveness Index, By Test
9.2. Lipid Panel*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Liver Panel
9.4. Renal Panel
9.5. Complete Blood Count
9.6. Electrolyte Testing
9.7. Infectious Disease Testing
9.8. Other Tests

10. By Product

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 10.1.2. Market Attractiveness Index, By Product
10.2. Instruments*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Reagents
10.4. Others

11. By End-user

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
11.1.2. Market Attractiveness Index, By End-user

11.2. Hospital Laboratory*
- 11.2.1. Introduction
- 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Diagnostic Laboratory
11.4. Point-of-care Testing
11.5. Others

12. By Region

12.1. Introduction
- 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 12.1.2. Market Attractiveness Index, By Region
12.2. North America
- 12.2.1. Introduction
- 12.2.2. Key Region-Specific Dynamics
- 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.2.6.1. U.S.
  - 12.2.6.2. Canada
  - 12.2.6.3. Mexico
12.3. Europe
- 12.3.1. Introduction
- 12.3.2. Key Region-Specific Dynamics
- 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.3.6.1. Germany
  - 12.3.6.2. U.K.
  - 12.3.6.3. France
  - 12.3.6.4. Italy
  - 12.3.6.5. Spain
  - 12.3.6.6. Rest of Europe
12.4. South America
- 12.4.1. Introduction
- 12.4.2. Key Region-Specific Dynamics
- 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.4.6.1. Brazil
  - 12.4.6.2. Argentina
  - 12.4.6.3. Rest of South America
12.5. Asia-Pacific
- 12.5.1. Introduction
- 12.5.2. Key Region-Specific Dynamics
- 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user
- 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 12.5.6.1. China
  - 12.5.6.2. India
  - 12.5.6.3. Japan
  - 12.5.6.4. Australia
  - 12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
- 12.6.1. Introduction
- 12.6.2. Key Region-Specific Dynamics
- 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test
- 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
- 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user

13. Competitive Landscape

13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies

14. Company Profiles

14.1. Abbott Laboratories*
- 14.1.1. Company Overview
- 14.1.2. Product Portfolio and Description
- 14.1.3. Financial Overview
- 14.1.4. Key Developments
14.2. Becton, Dickinson and Company
14.3. BioMerieux
14.4. Bio-Rad Laboratories Inc.
14.5. Danaher Corporation
14.6. Siemens AG
14.7. Hologic Inc.
14.8. Qiagen NV
14.9. F. Hoffmann-La Roche AG
14.10. Thermo Fisher Scientific

LIST NOT EXHAUSTIVE